BCG for Therapeutic Use Phase I Clinical Trial

Summary

This clinical study adopted a single-arm, open, single-centertrial design. The purpose of this study was to evaluate the safety and tolerability, PK characteristics, shedding and immune response characteristics of BCG for therapeutic use developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. in patients aged 18 and over after transethral resection of non-muscular invasive bladder cancer.

Timeline

Start

2023-11-22

Primary completion

2025-01-01

Completion

2025-04-30

Drugs

Indications